Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.32 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4338091 | 0.83 | POLB (0.32) | CYP2C19POLBDPP4 | |
| SCHEMBL25015671 | 0.81 | ALDH1A1 (0.34) | ALDH1A1POLBDPP4 | |
| SCHEMBL4346526 | 0.79 | POLB (0.30) | POLB | |
| SCHEMBL4340000 | 0.79 | PIK3CD (0.36) | CYP2D6CYP2C19POLB | |
| SCHEMBL19305362 | 0.76 | CYP2D6 (0.32) | CYP2D6CYP2C19TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL18730508 | 0.75 | ALDH1A1 (0.36) | CYP2D6CYP2C19ALDH1A1TSHRTAS1R3 | |
| SCHEMBL2934387 | 0.75 | ALDH1A1 (0.36) | CYP2D6CYP2C19ALDH1A1TSHRTAS1R3 | |
| SCHEMBL1583726 | 0.74 | DPP4 (0.37) | CYP2D6CYP2C19ALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL12538942 | 0.74 | CA1 (0.53) | CYP2D6TSHR | |
| SCHEMBL12538941 | 0.74 | CA1 (0.53) | CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220226298-A1 | GPR40 AGONISTS | KALLYOPE, INC. | 2022-07-21 | — | — | US | disclosed |
| WO-2020242943-A1 | GPR40 AGONISTS | KALLYOPE, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226298-A1 | GPR40 AGONISTS | GPR119, GPR65, GLP1R | CYP2D6 2098/4885CYP2C19 2187/4885ALDH1A1 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.